thalidomide - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

thalomid thalidomide 200 mg hard capsule blister pack

celgene pty ltd - thalidomide, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone; purified water; gelatin; sodium lauryl sulfate - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. thalomid is prescribed and dispensed through the thalidomide risk management pro

Malta - English - Medicines Authority

thalidomide milstein 50 mg hard capsules

milstein c.v. patroonsweg 20 e, 3892db zeewolde, , netherlands - hard capsule - thalidomide 50 mg - immunosuppressants

Australia - English - Department of Health (Therapeutic Goods Administration)

thalomid thalidomide 150 mg hard capsule blister pack

celgene pty ltd - thalidomide, quantity: 150 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; sorbitan monolaurate; caramel; potable water; gelatin; sodium lauryl sulfate; pharmaceutical glaze; dimeticone - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. multiple myeloma - thalomid in combination with melphalan and prednisone is indi

New Zealand - English - Medsafe (Medicines Safety Authority)

thalidomide pharmion

douglas pharmaceuticals limited - thalidomide 50mg - capsule - 50 mg - active: thalidomide 50mg excipient: colloidal silicon dioxide crospovidone gelatin lactose microcrystalline cellulose povidone stearic acid